{"id":529620,"date":"2021-08-19T07:03:23","date_gmt":"2021-08-19T11:03:23","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-announces-the-third-clinical-trial-collaboration-with-merck-to-advance-anti-cd137-agonist-adg106-in-combination-therapy-with-keytruda-pembrolizumab\/"},"modified":"2021-08-19T07:03:23","modified_gmt":"2021-08-19T11:03:23","slug":"adagene-announces-the-third-clinical-trial-collaboration-with-merck-to-advance-anti-cd137-agonist-adg106-in-combination-therapy-with-keytruda-pembrolizumab","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-announces-the-third-clinical-trial-collaboration-with-merck-to-advance-anti-cd137-agonist-adg106-in-combination-therapy-with-keytruda-pembrolizumab\/","title":{"rendered":"Adagene Announces the Third Clinical Trial Collaboration with Merck to Advance Anti-CD137 Agonist, ADG106, in Combination Therapy with KEYTRUDA\u00ae (pembrolizumab)"},"content":{"rendered":"<h2>\nCollaboration to evaluate NEObody\u2122 product candidate, ADG106, in combination with KEYTRUDA\u00ae for patients with advanced or metastatic solid and\/or hematological malignancies<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"justify\">SAN FRANCISCO, Aug.  19, 2021  (GLOBE NEWSWIRE) &#8212; Adagene Inc. (\u201cAdagene\u201d) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announced that it has entered into a third clinical trial collaboration and supply agreement with Merck (known as \u201cMSD\u201d outside the United States and Canada).\u00a0The agreement includes an open-label, dose escalation and expansion clinical study of ADG106 in combination with Merck\u2019s anti-PD-1 KEYTRUDA<sup><strong>\u00ae<\/strong><\/sup> (pembrolizumab) in advanced or metastatic solid and\/or hematological malignancies (ADG106-P2001\/KEYNOTE-D12). This clinical study builds on the promising monotherapy and combination therapy data from a Phase I trial of ADG106. Engineered using Adagene\u2019s proprietary NEObody\u2122 platform technology, ADG106 is a fully human, ligand-blocking, agonistic anti-CD137 immunoglobulin G4 (IgG4) monoclonal antibody (mAb).<\/p>\n<p align=\"justify\">\u201cWe are excited to continue our partnership with Merck in a third clinical collaboration that now combines our anti-CD137 agonist, ADG106, with KEYTRUDA,\u201d said Peter Luo, Ph.D., Co-founder, Chief Executive Officer and Chairman of Adagene. \u201cWhile PD-1 drugs have advanced the cancer treatment paradigm, there are still a substantial number of patients with advanced metastatic solid and hematological malignancies who either relapse or are unresponsive, highlighting the need for new approaches. ADG106 targets a unique and highly conserved epitope with a novel mechanism of action and broad species cross reactivity, which enables testing in immunocompetent hosts. In multiple syngeneic models, we have shown a strong additive effect between ADG106 and anti-PD-1\/PD-L1 agents.\u201d<\/p>\n<p align=\"justify\">\u201cWe look forward to working closely with Merck and combining ADG106 with KEYTRUDA,\u201d said Steven Fischkoff, M.D., interim Chief Medical Officer of Adagene. \u201cTogether with our novel mechanism of action, extensive preclinical and strong clinical data generated to date, we believe ADG106 is an ideal candidate to combine with an anti-PD1 antibody to potentially create a new therapeutic option for cancer patients with unmet medical needs.\u201d<\/p>\n<p align=\"justify\">KEYTRUDA<sup>\u00ae<\/sup>\u00a0is a registered trademark of\u00a0Merck Sharp &amp; Dohme Corp., a subsidiary of Merck &amp; Co., Inc.,\u00a0Kenilworth, NJ, USA.<\/p>\n<p align=\"justify\">\n        <strong>About <\/strong><br \/>\n        <strong>ADG106<\/strong><br \/>\n        <br \/>ADG106, is a fully human ligand-blocking, agonistic anti-CD137 IgG4 mAb being developed for the treatment of advanced solid tumors and non-Hodgkin\u2019s lymphoma. CD137 stimulates the immune system to attack cancer cells and is a key driver for long-lasting T cell proliferation and survival. In preclinical studies, we observed that ADG106 had robust antitumor activity and was well tolerated as a single agent and in combination with the existing standard-of-care and other immuno-oncology therapies. ADG106 activates CD137 in a native ligand-like fashion, blocks reverse CD137 ligand signaling, and induces potent cross-linking by Fc receptors. Because of this novel mechanism of action, ADG106 was observed to favorably balance CD137 agonism over CD137-induced liver toxicity, which we believe has potential to address the limitations of other existing anti-CD137 therapies.<\/p>\n<p align=\"justify\">ADG106 Phase I trials have been successfully completed with enrollment of nearly 100 patients with advanced solid tumors and non-Hodgkin\u2019s lymphoma in the United States and China. Based on the promising Phase I data, ADG106 is being evaluated in a Phase Ib\/II combination study in advanced solid tumors and relapsed\/refractory non-Hodgkin lymphoma.<\/p>\n<p align=\"justify\">\n        <strong>About Adagene<\/strong><br \/>\n        <br \/>Adagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational biology and artificial intelligence to design novel antibodies that address unmet patient needs. Powered by its proprietary DPL platform, composed of NEObody, SAFEbody\u2122, and POWERbody\u2122 technologies, Adagene\u2019s highly differentiated pipeline features novel immunotherapy programs. Adagene has forged strategic collaborations with reputable global partners that leverage its technology in multiple approaches at the vanguard of science.<\/p>\n<p align=\"justify\">For more information, please visit:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Pcli52RMXIFBmyuzmXrODh6z0is8w0pG93XcPy4qdyKOAX_AzaWHT0IoUlWWdtssRZXK6gVt9-H5ouYL3HaACOxcobo-OsGTWjgO4CubtG4=\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/investor.adagene.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Safe Harbor Statement<\/strong><br \/>\n        <br \/>This press release contains forward-looking statements, including statements regarding the therapeutic potential of ADG106 in combination with pembrolizumab to treat patients with advanced\/metastatic solid and\/or hematological malignancies, data from the ADG106 clinical trials, clinical development plans of ADG106, the potential implications of clinical data for patients, and Adagene\u2019s advancement of, and anticipated clinical development, regulatory milestones and commercialization of ADG106. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including but not limited to the potential failure of the combination of ADG106 and pembrolizumab to demonstrate safety and\/or efficacy in the Phase 1 open-label, dose escalation and expansion studies; the clinical results for Adagene\u2019s drug candidates, which may not support further development or regulatory approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of Adagene\u2019s drug candidates; Adagene\u2019s ability to achieve commercial success for its drug candidates, if approved; Adagene\u2019s ability to obtain and maintain protection of intellectual property for its technology and drugs; Adagene\u2019s reliance on third parties to conduct drug development, manufacturing and other services; Adagene\u2019s limited operating history and Adagene\u2019s ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates; Adagene\u2019s ability to enter into additional collaboration agreements beyond its existing strategic partnerships or collaborations, and the impact of the COVID-19 pandemic on Adagene\u2019s clinical development, commercial and other operations, as well as those risks more fully discussed in the \u201cRisk Factors\u201d section in Adagene\u2019s filings with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Adagene, and Adagene undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.<\/p>\n<p>\n        <strong>Internal Contact<\/strong>:<br \/>Ami Knoefler<br \/>Adagene<br \/>650-739-9952<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=WYX9JGAYAe_yHjeCWhdGvHcaZJh0P-vcDnM3VOyw-mAQ_UdnHNMHEACLsxe59xn4UXZ6v0yYCVYbJU5Ro3XzcQ==\" rel=\"nofollow noopener\" target=\"_blank\">ir@adagene.com<\/a><\/p>\n<p>\n        <strong>External Contact: <\/strong><br \/>\n        <br \/>Bruce Mackle<br \/>LifeSci Advisors<br \/>646-889-1200<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2TxS2Ij4eHA8FyepAZkQ6z0vNlCDW_OIx8lziU9pV4pAHA_kvOHl4ngny2IPDRfXjUWNLyNMf-EFxkl5Bpn7A0kWOv7sMtn-YF8_-wZWYavbLtiL5wvsNOtlo1742EgK\" rel=\"nofollow noopener\" target=\"_blank\">bmackle@lifesciadvisors.com<\/a><\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxMTgyNCM0MzY1MjgyIzIyMDQ2ODE=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MjRjNWEyYmEtYzI0Ny00ZjdmLWIzZmMtOGM4M2U4YTA3ZmEyLTEyMTYyMzQ=\/tiny\/Adagene-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Collaboration to evaluate NEObody\u2122 product candidate, ADG106, in combination with KEYTRUDA\u00ae for patients with advanced or metastatic solid and\/or hematological malignancies SAN FRANCISCO, Aug. 19, 2021 (GLOBE NEWSWIRE) &#8212; Adagene Inc. (\u201cAdagene\u201d) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announced that it has entered into a third clinical trial collaboration and supply agreement with Merck (known as \u201cMSD\u201d outside the United States and Canada).\u00a0The agreement includes an open-label, dose escalation and expansion clinical study of ADG106 in combination with Merck\u2019s anti-PD-1 KEYTRUDA\u00ae (pembrolizumab) in advanced or metastatic solid and\/or hematological malignancies (ADG106-P2001\/KEYNOTE-D12). This clinical study builds on the promising monotherapy and combination therapy data from a Phase I &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-announces-the-third-clinical-trial-collaboration-with-merck-to-advance-anti-cd137-agonist-adg106-in-combination-therapy-with-keytruda-pembrolizumab\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Adagene Announces the Third Clinical Trial Collaboration with Merck to Advance Anti-CD137 Agonist, ADG106, in Combination Therapy with KEYTRUDA\u00ae (pembrolizumab)&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-529620","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Adagene Announces the Third Clinical Trial Collaboration with Merck to Advance Anti-CD137 Agonist, ADG106, in Combination Therapy with KEYTRUDA\u00ae (pembrolizumab) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-announces-the-third-clinical-trial-collaboration-with-merck-to-advance-anti-cd137-agonist-adg106-in-combination-therapy-with-keytruda-pembrolizumab\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Adagene Announces the Third Clinical Trial Collaboration with Merck to Advance Anti-CD137 Agonist, ADG106, in Combination Therapy with KEYTRUDA\u00ae (pembrolizumab) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Collaboration to evaluate NEObody\u2122 product candidate, ADG106, in combination with KEYTRUDA\u00ae for patients with advanced or metastatic solid and\/or hematological malignancies SAN FRANCISCO, Aug. 19, 2021 (GLOBE NEWSWIRE) &#8212; Adagene Inc. (\u201cAdagene\u201d) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announced that it has entered into a third clinical trial collaboration and supply agreement with Merck (known as \u201cMSD\u201d outside the United States and Canada).\u00a0The agreement includes an open-label, dose escalation and expansion clinical study of ADG106 in combination with Merck\u2019s anti-PD-1 KEYTRUDA\u00ae (pembrolizumab) in advanced or metastatic solid and\/or hematological malignancies (ADG106-P2001\/KEYNOTE-D12). This clinical study builds on the promising monotherapy and combination therapy data from a Phase I &hellip; Continue reading &quot;Adagene Announces the Third Clinical Trial Collaboration with Merck to Advance Anti-CD137 Agonist, ADG106, in Combination Therapy with KEYTRUDA\u00ae (pembrolizumab)&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-announces-the-third-clinical-trial-collaboration-with-merck-to-advance-anti-cd137-agonist-adg106-in-combination-therapy-with-keytruda-pembrolizumab\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-08-19T11:03:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxMTgyNCM0MzY1MjgyIzIyMDQ2ODE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adagene-announces-the-third-clinical-trial-collaboration-with-merck-to-advance-anti-cd137-agonist-adg106-in-combination-therapy-with-keytruda-pembrolizumab\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adagene-announces-the-third-clinical-trial-collaboration-with-merck-to-advance-anti-cd137-agonist-adg106-in-combination-therapy-with-keytruda-pembrolizumab\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Adagene Announces the Third Clinical Trial Collaboration with Merck to Advance Anti-CD137 Agonist, ADG106, in Combination Therapy with KEYTRUDA\u00ae (pembrolizumab)\",\"datePublished\":\"2021-08-19T11:03:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adagene-announces-the-third-clinical-trial-collaboration-with-merck-to-advance-anti-cd137-agonist-adg106-in-combination-therapy-with-keytruda-pembrolizumab\\\/\"},\"wordCount\":986,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adagene-announces-the-third-clinical-trial-collaboration-with-merck-to-advance-anti-cd137-agonist-adg106-in-combination-therapy-with-keytruda-pembrolizumab\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMxMTgyNCM0MzY1MjgyIzIyMDQ2ODE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adagene-announces-the-third-clinical-trial-collaboration-with-merck-to-advance-anti-cd137-agonist-adg106-in-combination-therapy-with-keytruda-pembrolizumab\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adagene-announces-the-third-clinical-trial-collaboration-with-merck-to-advance-anti-cd137-agonist-adg106-in-combination-therapy-with-keytruda-pembrolizumab\\\/\",\"name\":\"Adagene Announces the Third Clinical Trial Collaboration with Merck to Advance Anti-CD137 Agonist, ADG106, in Combination Therapy with KEYTRUDA\u00ae (pembrolizumab) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adagene-announces-the-third-clinical-trial-collaboration-with-merck-to-advance-anti-cd137-agonist-adg106-in-combination-therapy-with-keytruda-pembrolizumab\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adagene-announces-the-third-clinical-trial-collaboration-with-merck-to-advance-anti-cd137-agonist-adg106-in-combination-therapy-with-keytruda-pembrolizumab\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMxMTgyNCM0MzY1MjgyIzIyMDQ2ODE=\",\"datePublished\":\"2021-08-19T11:03:23+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adagene-announces-the-third-clinical-trial-collaboration-with-merck-to-advance-anti-cd137-agonist-adg106-in-combination-therapy-with-keytruda-pembrolizumab\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adagene-announces-the-third-clinical-trial-collaboration-with-merck-to-advance-anti-cd137-agonist-adg106-in-combination-therapy-with-keytruda-pembrolizumab\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adagene-announces-the-third-clinical-trial-collaboration-with-merck-to-advance-anti-cd137-agonist-adg106-in-combination-therapy-with-keytruda-pembrolizumab\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMxMTgyNCM0MzY1MjgyIzIyMDQ2ODE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMxMTgyNCM0MzY1MjgyIzIyMDQ2ODE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adagene-announces-the-third-clinical-trial-collaboration-with-merck-to-advance-anti-cd137-agonist-adg106-in-combination-therapy-with-keytruda-pembrolizumab\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Adagene Announces the Third Clinical Trial Collaboration with Merck to Advance Anti-CD137 Agonist, ADG106, in Combination Therapy with KEYTRUDA\u00ae (pembrolizumab)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Adagene Announces the Third Clinical Trial Collaboration with Merck to Advance Anti-CD137 Agonist, ADG106, in Combination Therapy with KEYTRUDA\u00ae (pembrolizumab) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-announces-the-third-clinical-trial-collaboration-with-merck-to-advance-anti-cd137-agonist-adg106-in-combination-therapy-with-keytruda-pembrolizumab\/","og_locale":"en_US","og_type":"article","og_title":"Adagene Announces the Third Clinical Trial Collaboration with Merck to Advance Anti-CD137 Agonist, ADG106, in Combination Therapy with KEYTRUDA\u00ae (pembrolizumab) - Market Newsdesk","og_description":"Collaboration to evaluate NEObody\u2122 product candidate, ADG106, in combination with KEYTRUDA\u00ae for patients with advanced or metastatic solid and\/or hematological malignancies SAN FRANCISCO, Aug. 19, 2021 (GLOBE NEWSWIRE) &#8212; Adagene Inc. (\u201cAdagene\u201d) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announced that it has entered into a third clinical trial collaboration and supply agreement with Merck (known as \u201cMSD\u201d outside the United States and Canada).\u00a0The agreement includes an open-label, dose escalation and expansion clinical study of ADG106 in combination with Merck\u2019s anti-PD-1 KEYTRUDA\u00ae (pembrolizumab) in advanced or metastatic solid and\/or hematological malignancies (ADG106-P2001\/KEYNOTE-D12). This clinical study builds on the promising monotherapy and combination therapy data from a Phase I &hellip; Continue reading \"Adagene Announces the Third Clinical Trial Collaboration with Merck to Advance Anti-CD137 Agonist, ADG106, in Combination Therapy with KEYTRUDA\u00ae (pembrolizumab)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-announces-the-third-clinical-trial-collaboration-with-merck-to-advance-anti-cd137-agonist-adg106-in-combination-therapy-with-keytruda-pembrolizumab\/","og_site_name":"Market Newsdesk","article_published_time":"2021-08-19T11:03:23+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxMTgyNCM0MzY1MjgyIzIyMDQ2ODE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-announces-the-third-clinical-trial-collaboration-with-merck-to-advance-anti-cd137-agonist-adg106-in-combination-therapy-with-keytruda-pembrolizumab\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-announces-the-third-clinical-trial-collaboration-with-merck-to-advance-anti-cd137-agonist-adg106-in-combination-therapy-with-keytruda-pembrolizumab\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Adagene Announces the Third Clinical Trial Collaboration with Merck to Advance Anti-CD137 Agonist, ADG106, in Combination Therapy with KEYTRUDA\u00ae (pembrolizumab)","datePublished":"2021-08-19T11:03:23+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-announces-the-third-clinical-trial-collaboration-with-merck-to-advance-anti-cd137-agonist-adg106-in-combination-therapy-with-keytruda-pembrolizumab\/"},"wordCount":986,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-announces-the-third-clinical-trial-collaboration-with-merck-to-advance-anti-cd137-agonist-adg106-in-combination-therapy-with-keytruda-pembrolizumab\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxMTgyNCM0MzY1MjgyIzIyMDQ2ODE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-announces-the-third-clinical-trial-collaboration-with-merck-to-advance-anti-cd137-agonist-adg106-in-combination-therapy-with-keytruda-pembrolizumab\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-announces-the-third-clinical-trial-collaboration-with-merck-to-advance-anti-cd137-agonist-adg106-in-combination-therapy-with-keytruda-pembrolizumab\/","name":"Adagene Announces the Third Clinical Trial Collaboration with Merck to Advance Anti-CD137 Agonist, ADG106, in Combination Therapy with KEYTRUDA\u00ae (pembrolizumab) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-announces-the-third-clinical-trial-collaboration-with-merck-to-advance-anti-cd137-agonist-adg106-in-combination-therapy-with-keytruda-pembrolizumab\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-announces-the-third-clinical-trial-collaboration-with-merck-to-advance-anti-cd137-agonist-adg106-in-combination-therapy-with-keytruda-pembrolizumab\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxMTgyNCM0MzY1MjgyIzIyMDQ2ODE=","datePublished":"2021-08-19T11:03:23+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-announces-the-third-clinical-trial-collaboration-with-merck-to-advance-anti-cd137-agonist-adg106-in-combination-therapy-with-keytruda-pembrolizumab\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/adagene-announces-the-third-clinical-trial-collaboration-with-merck-to-advance-anti-cd137-agonist-adg106-in-combination-therapy-with-keytruda-pembrolizumab\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-announces-the-third-clinical-trial-collaboration-with-merck-to-advance-anti-cd137-agonist-adg106-in-combination-therapy-with-keytruda-pembrolizumab\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxMTgyNCM0MzY1MjgyIzIyMDQ2ODE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxMTgyNCM0MzY1MjgyIzIyMDQ2ODE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-announces-the-third-clinical-trial-collaboration-with-merck-to-advance-anti-cd137-agonist-adg106-in-combination-therapy-with-keytruda-pembrolizumab\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Adagene Announces the Third Clinical Trial Collaboration with Merck to Advance Anti-CD137 Agonist, ADG106, in Combination Therapy with KEYTRUDA\u00ae (pembrolizumab)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/529620","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=529620"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/529620\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=529620"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=529620"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=529620"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}